Advertisement
UK markets closed

  • NIKKEI 225

    33,408.39
    -39.28 (-0.12%)
     

  • HANG SENG

    17,354.14
    -170.92 (-0.98%)
     

  • CRUDE OIL

    76.52
    +1.66 (+2.22%)
     

  • GOLD FUTURES

    2,042.80
    +30.40 (+1.51%)
     

  • DOW

    35,416.98
    +83.51 (+0.24%)
     

  • Bitcoin GBP

    29,887.99
    +712.62 (+2.44%)
     

  • CMC Crypto 200

    785.88
    +21.19 (+2.77%)
     

  • NASDAQ Composite

    14,281.76
    +40.73 (+0.29%)
     

  • UK FTSE All Share

    4,059.87
    -4.31 (-0.11%)
     
Money:

Are you missing out on thousands of pounds in lost pension income?

If you lose track of one of your pensions, you could be leaving yourself worse off in retirement

Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe

Alex Carchidi, The Motley Fool
·4-min read
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe

Recursion Pharmaceuticals (NASDAQ: RXRX) and 23andMe (NASDAQ: ME) are both popular biotech stocks that are wooing investors with their claims about using artificial intelligence (AI) to supercharge the drug development process. Let's examine their prospects and determine which of these two biotech stocks is the better investment. 23andMe is famous for its consumer genetic testing business, which accounted for 79% of its $61 million in total revenue for its fiscal 2024 first quarter (ended June 30).

Continue reading